Numerous neurodegenerative diseases are characterized by the accumulation of tau aggregates. There are 20 known tauopathies; Alzheimer’s disease is by far the most prevalent (6.7 million in the US). The others are generally rare diseases with US prevalence ranging from 50-60 thousand for frontotemporal dementia (FTD) and 10 - 20 thousand for most others.
Oligomerix is discovering and developing therapeutics for neurodegeneration and dementias, including progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), ALS and Alzheimer’s disease (AD), characterized by the accumulation of tau aggregates.
By targeting tau self-association at the beginning of the tau cascade, our lead compound has shown in multiple animal models to prevent downstream tau aggregation. Given the significant unmet needs in neurodegenerative tauopathies, Oligomerix is focused on developing disease-modifying treatments initially in rare disease tauopathies such as PSP and FTD. Furthermore, the Company has recently begun to characterize its 2nd generation series of small molecule tau aggregation inhibitors.
Targeting tau oligomers can lead to the development of effective treatments for these diseases:
There is a rapidly increasing disease incidence and prevalence of AD and related dementias due to aging populations worldwide. Global dementia prevalence is expected to increase from 57 million in 2019 to 153 million in 2050, a 268% increase. In the US alone, AD prevalence is expected to increase from 6.7 million in 2023 to 12.7 million by 2050.
Alzheimer’s disease signs and symptoms include the following; the severity of these signs and symptoms worsens over the course of the disease.
- Loss of memory, with an associated decline in the ability to communicate.
- Declining ability to manage activities of daily living, such as bathing, dressing, and feeding.
- Patients become more confused, often forgetting their whereabouts and sense of time.
- Challenges in planning or solving problems.
- Patients tend to develop poor judgment. Some may become depressed or anxious, others may become angry or belligerent.
Alzheimer’s disease is one of the costliest in the US healthcare system, with total direct costs estimated at $321 billion in 2022, projected to increase to $1 trillion by 2050. And this does not include the indirect costs associated with unpaid caregivers, who in 2021 provided an estimated 16 billion hours valued at $271 billion.
Patient Advocacy Groups